- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sandoz Announces European Approval of Biosimilar Rituximab
Sandoz announced today that its biosimilar rituximab product has been approved by the European Commission to treat blood cancers and immunological diseases.
Sandoz announced today that its biosimilar rituximab product has been approved by the European Commission to treat blood cancers and immunological diseases. Sandoz’s product will be marketed as both Rixathon and Riximyo under a duplicate marketing authorization.
Sandoz’s rituximab is approved for use in all indications of its reference, Roche’s MabThera, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
The European Commission based its approval on analytical, preclinical, and clinical data, including pharmacokinetic (PK) and pharmacodynamic (PD) data that demonstrated equivalent safety, efficacy, and quality of the biosimilar and reference treatments. Clinical studies for the biosimilar included a phase 3 efficacy and safety study in patients with previously untreated advanced follicular lymphoma. The study met its primary endpoint of demonstrating equivalence in overall response rate to the reference product, and additionally demonstrated similarity in efficacy, PK and PD.
"Today's approval of Rixathon represents a big win for patients in Europe with blood cancers or immunological diseases because it enables increased access to biologics,” said Carol Lynch, global head of biopharmaceuticals at Sandoz. “It also allows healthcare systems to redeploy resources to other areas of high need, particularly innovative therapies," Lynch added.
Sandoz’s product joins Celltrion’s Truxima, another biosimilar rituximab, in the European marketplace. Celltrion’s product, granted European authorization in February of 2017, has already been supplied to 50 hospitals in the United Kingdom. According to Celltrion, patient populations treated with Truxima included patients who were switched to the biosimilar. Competition from Sandoz and Celltrion poses a challenge to Roche, which relied on its innovative product for approximately $7.2 billion of its global sales in 2016.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
